5 active not recruiting, 5 recruiting. 6 Phase 2, 4 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 6 | Active not recruiting 4, Recruiting 2 |
| Phase 3 | 4 | Recruiting 3, Active not recruiting 1 |
Follow Lenacapavir Tablet: new trials by email Literature Review of Lenacapavir Tablet trials Research Report on Lenacapavir Tablet
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study of an Injectable Regimen of GS-3242 With Lenacapavir Compared to Biktarvy in People New to HIV-1 Treatment GS-3242 Tablet, GS-3242 Injection, Lenacapavir Tablet - HIV-1-infection | Phase 2 / Phase 3 | Recruiting | Gilead Sciences | 700 | 2026-07-29 | 2026-11-10 |
| Study of Lenacapavir, Teropavimab, and Zinlirvimab Versus Cabotegravir and Rilpivirine in Virologically Suppressed Adults With HIV-1 on Oral Daily Antiretroviral Therapy Lenacapavir, Lenacapavir Tablet, Teropavimab - HIV Infections | Phase 3 | Recruiting | Gilead Sciences | 590 | 2026-07-14 | 2026-08-14 |
| Study of Lenacapavir, Teropavimab, and Zinlirvimab in Virologically Suppressed Adults With HIV-1 on Stable Oral Treatment Regimens Lenacapavir, Lenacapavir Tablet, Teropavimab - HIV-1-infection | Phase 3 | Recruiting | Gilead Sciences | 590 | 2026-07-14 | 2026-07-30 |
| A Study of GS-3242 in Combination With Lenacapavir Versus Biktarvy in Virologically Suppressed People With HIV-1 GS-3242 Tablet, GS-3242 Injection, Lenacapavir Tablet - HIV-1-infection | Phase 2 | Recruiting | Gilead Sciences | 175 | 2026-06-15 | 2026-11-10 |
| Implementation Study of Lenacapavir Pre-exposure Prophylaxis for HIV Prevention Lenacapavir Injection, Emtricitabine/tenofovir disoproxil fumarate (F/TDF), Emtricitabine/tenofovir alafenamide (F/TAF) - HIV Infections | Recruiting | Gilead Sciences | 3000 | 2026-03-17 | 2026-10-21 | |
| Study of Lenacapavir as a Once-Yearly Injection for HIV Pre-exposure Prophylaxis (PrEP) Lenacapavir Injection, Lenacapavir Tablet - HIV Pre-exposure Prophylaxis | Phase 3 | Active not recruiting | Gilead Sciences | 339 | 2025-07-22 | 2026-08-28 |
| Study of Lenacapavir Taken Twice a Year for HIV Pre-Exposure Prophylaxis (PrEP) Lenacapavir Injection, Lenacapavir Tablet, Emtricitabine/tenofovir disoproxil fumarate (F/TDF) - Pre-Exposure Prophylaxis of HIV Infection | Phase 2 | Active not recruiting | Gilead Sciences | 268 | 2024-10-07 | 2026-06-15 |
| Study of Lenacapavir and Emtricitabine/Tenofovir Disoproxil Fumarate (F/TDF) for Prevention of HIV in People Who Inject Drugs (HPTN 103) Lenacapavir Injection, Lenacapavir Tablet, Emtricitabine/tenofovir disoproxil fumarate (F/TDF) - Pre-Exposure Prophylaxis of HIV Infection | Phase 2 | Active not recruiting | Gilead Sciences | 181 | 2023-12-13 | 2026-08-13 |
| Study of Lenacapavir and Emtricitabine/Tenofovir Disoproxil Fumarate (F/TDF) in Prevention of HIV in Cisgender Women in the United States (HPTN 102) Lenacapavir Tablet, Lenacapavir Injection, Emtricitabine/Tenofovir Disoproxil Fumarate (F/TDF) - Pre-Exposure Prophylaxis of HIV Infection | Phase 2 | Active not recruiting | Gilead Sciences | 253 | 2023-11-17 | 2026-08-17 |
| A Study of Teropavimab and Zinlirvimab in Combination With Capsid Inhibitor Lenacapavir in Virologically Suppressed Adults With HIV-1 Infection Teropavimab, Zinlirvimab, Lenacapavir Tablet - HIV-1 Infection | Phase 2 | Active not recruiting | Gilead Sciences | 83 | 2023-05-15 | 2026-04-27 |
HIV Infections (2)
Gilead Sciences (10)
United States (9) · Australia (3) · Canada (3) · Puerto Rico (3) · France (1) · Germany (1) · Japan (1) · Spain (1) · United Kingdom (1)
2025 (2), 2023 (1)